Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Axsome Therapeutics Inc (DE:19X)
FRANKFURT:19X
Holding DE:19X?
Track your performance easily
19X Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€52.42 - €91.90
Previous Close€85.44
Volume150.00
Average Volume (3M)96.00
Market Cap
€4.05B
Enterprise Value€3.94B
Total Cash (Recent Filing)$315.66M
Total Debt (Recent Filing)$190.60M
Price to Earnings (P/E)―
Beta0.56
Next Earnings
Nov 04, 2024EPS Estimate
-€1.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding48,000,205
10 Day Avg. Volume28
30 Day Avg. Volume96
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)110.45
Price to Sales (P/S)15.43
Price to Cash Flow (P/CF)-37.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue13.52
Enterprise Value/Gross Profit16.12
Enterprise Value/Ebitda-13.31
Forecast
1Y Price Target
€109.10Price Target Upside27.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
Axsome Therapeutics News
Bulls Say, Bears Say
Bulls Say
Commercial ProgressThe percent of commercial lives covered has increased to 60% as of 8/1/24.
Intellectual PropertyThe dismissal of this patent litigation and the withdrawal of the Sandoz ANDA for generic solriamfetol constitutes a meaningful win, as it demonstrates the strength of Axsome's intellectual property (IP) estate on Sunosi and also ensures the removal of a potential generic threat.
Regulatory ApprovalThe FDA has accepted for review the resubmission of the company’s AXS-07 New Drug Application for the acute treatment of migraine.
Bears Say
Financial PerformanceGrowing opex pushed EPS to the more negative end of the consensus range.
Regulatory ConcernsA short report raised concerns regarding revenue recognition of Auvelity sales and alleged improper selling practices.
SalesBuyside expectations exceeded the reported sales.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.50% Insiders
19.67% Mutual Funds
56.47% Other Institutional Investors
23.36% Public Companies and
Individual Investors
19X FAQ
What was Axsome Therapeutics Inc’s price range in the past 12 months?
Axsome Therapeutics Inc lowest stock price was €52.42 and its highest was €91.90 in the past 12 months.
What is Axsome Therapeutics Inc’s market cap?
Currently, no data Available
When is Axsome Therapeutics Inc’s upcoming earnings report date?
Axsome Therapeutics Inc’s upcoming earnings report date is Nov 04, 2024 which is in 57 days.
How were Axsome Therapeutics Inc’s earnings last quarter?
Axsome Therapeutics Inc released its earnings results on Aug 05, 2024. The company reported -€1.511 earnings per share for the quarter, missing the consensus estimate of -€1.183 by -€0.328.
Is Axsome Therapeutics Inc overvalued?
According to Wall Street analysts Axsome Therapeutics Inc’s price is currently Undervalued.
Does Axsome Therapeutics Inc pay dividends?
Axsome Therapeutics Inc does not currently pay dividends.
What is Axsome Therapeutics Inc’s EPS estimate?
Axsome Therapeutics Inc’s EPS estimate is -€1.22.
How many shares outstanding does Axsome Therapeutics Inc have?
Axsome Therapeutics Inc has 48,000,206 shares outstanding.
What happened to Axsome Therapeutics Inc’s price movement after its last earnings report?
Axsome Therapeutics Inc reported an EPS of -€1.511 in its last earnings report, missing expectations of -€1.183. Following the earnings report the stock price went down -7.4%.
Which hedge fund is a major shareholder of Axsome Therapeutics Inc?
Among the largest hedge funds holding Axsome Therapeutics Inc’s share is Fairmount Funds Management Llc. It holds Axsome Therapeutics Inc’s shares valued at 190M.
---
Axsome Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€109.10 (27.69% Upside)
€109.10 (27.69% Upside)
Blogger Sentiment
Bullish
DE:19X Sentiment 100%
Sector Average 69%
Sector Average 69%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
14.29%
12-Months-Change
Fundamentals
Return on Equity
-161.69%
Trailing 12-Months
Asset Growth
-10.37%
Trailing 12-Months
Company Description
Axsome Therapeutics Inc
Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
---
19X Earnings Call
Q2 2024
0:00 / 0:00
---
19X Stock 12 Month Forecast
Average Price Target
€109.10
▲(27.69% Upside)
Technical Analysis
Axsome Therapeutics
―
ACADIA Pharmaceuticals
―
Arvinas Holding Company
―
Blueprint Medicines
―
Prothena
―
Best Analysts Covering 19X
1 Year
1 Year Success Rate
15/16 ratings generated profit
1 Year Average Return
+51.34%
assigned a buy rating last month
Copying Joon Lee's trades and holding each position for 1 Year would result in 93.75% of your transactions generating a profit, with an average return of +51.34% per trade.
---